Indomethacin analogs for the treatment of castrate-resistant prostate cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 20, 2018
Issued Date -
N/A
app pub date -
Apr 19, 2016
filing date -
Oct 17, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2016 Application Filing Year
- A61K Class
- 19101 Applications Filed
- 13019 Patents Issued To-Date
- 68.16 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 2 Citation Count
- A61K Class
- 50.93 % this patent is cited more than
- 7 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Aug 20, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Aug 20, 2029 |
